资源类型:
期刊
Pubmed体系:
Journal Article
文章类型:
论著
机构:
[1]Guangzhou Orthopedics Hospital, 449 Dongfeng Road, Yuexiu District, Guangzhou, Guangdong Province, 510045, China
[2]Department of Orthopedics, School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong Province 510515, China
ISSN:
0753-3322
关键词:
ZBTB4
Survivin
Ewing sarcoma
Proliferation
Apoptosis
Cell cycle
摘要:
Increasing studies identify that zinc finger and BTB domain containing 4 (ZBTB4) functions as a tumor suppressor in human cancer. Underexpression of ZBTB4 is correlated with poor survival of breast cancer patients. However, the expression of ZBTB4 and its possible function remain unknown in Ewing sarcoma (ES). To clarify these issues, we investigated the expression difference between ES and normal tissues based on Gene Expression Omnibus (GEO) data from R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl). GEO data (GSE68776) indicated that the expression of ZBTB4 in ES tissues was prominently lower compare to normal tissues. Our data further confirmed the underexpression of ZBTB4 in ES tissues. GEO data (GSE63157 and GSE17679) demonstrated that ZBTB4 underexpression predicted a obvious shorter overall survival and event-free survival of ES patients. Interestingly, the expression of ZBTB4 was inversely correlated with proliferation makers Ki-67 and proliferating cell nuclear antigen (PCNA) in ES tissues. In vitro, ZBTB4 overexpression inhibited cell proliferation, and induced cell cycle arrest at G1 phase and apoptosis in SK-ES-1 and RD-ES cells. Moreover, ZBTB4 restoration suppressed the tumor growth of ES in mice. An inversely correlation between ZBTB4 and Survivin expression was observed in ES tissues. ZBTB4 overexpression reduced Survivin abundance in ES cells. Notably, Survivin restoration reversed the regulatory effect of ZBTB4 on ES cell proliferation, cell cycle progression and apoptosis. To conclude, our data indicated that ZBTB4 exhibited a tumor suppressive role in ES possibly by reducing Survivin expression. ZBTB4/Survivin axis might serve as a therapeutic target for ES.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.
基金:
This study was supported by the Major Projects for Industry-university-
research Collaborative Innovation of Science and Technology
Plan of Guangzhou (no. 201604020095), Natural Science Foundation of
Guangdong Province (no. 2015A030313367), Project of Administration
of Traditional Chinese Medicine of Guangdong Province (no.20161164)
and 13th Five-Year the Province Project by the Guangdong Provincial
Administration of Traditional Chinese Medicine Management.
PubmedID:
29425745
中科院(CAS)分区:
出版当年[2017]版:
大类
|
3 区
医学
小类
|
3 区
药学
4 区
医学:研究与实验
最新[2025]版:
大类
|
2 区
医学
小类
|
2 区
医学:研究与实验
2 区
药学
第一作者:
Yu Yongxin
第一作者机构:
[1]Guangzhou Orthopedics Hospital, 449 Dongfeng Road, Yuexiu District, Guangzhou, Guangdong Province, 510045, China
通讯作者:
Shang Ruguo;Chen Chao
推荐引用方式(GB/T 7714):
Yu Yongxin,Shang Ruguo,Chen Yunzhou,et al.Tumor suppressive ZBTB4 inhibits cell growth by regulating cell cycle progression and apoptosis in Ewing sarcoma.[J].BIOMEDICINE & PHARMACOTHERAPY.2018,100:108-115.doi:10.1016/j.biopha.2018.01.132.
APA:
Yu Yongxin,Shang Ruguo,Chen Yunzhou,Li Jiehua,Liang Zhichao...&Chen Chao.(2018).Tumor suppressive ZBTB4 inhibits cell growth by regulating cell cycle progression and apoptosis in Ewing sarcoma..BIOMEDICINE & PHARMACOTHERAPY,100,
MLA:
Yu Yongxin,et al."Tumor suppressive ZBTB4 inhibits cell growth by regulating cell cycle progression and apoptosis in Ewing sarcoma.".BIOMEDICINE & PHARMACOTHERAPY 100.(2018):108-115